Medical screening tests lead to significant overdiagnosis and overtreatment
the verdict
SUPPORTED
the evidence backs this
confidence 95/100
Medical screening tests frequently lead to the detection of indolent, non-lethal conditions, resulting in significant overdiagnosis and subsequent overtreatment across various cancers such as prostate, breast, thyroid, and lung.
Evidence for · 7
Screening for Prostate Cancer
2018 · cited by 1,439
The USPSTF screening guidelines explicitly note that prostate cancer screening frequently leads to overdiagnosis and subsequent overtreatment.
See more details
More for · 6
The benefits and harms of breast cancer screening: an independent review
2013 · cited by 1,076
A comprehensive independent review of breast cancer screening highlights overdiagnosis as a major harm, noting that many screen-detected cancers would not have become clinically apparent.
Overdiagnosis and overtreatment of early detected prostate cancer
2007 · cited by 168
Early detection of prostate cancer frequently identifies indolent tumors, leading to the primary threat of overtreatment.
Overdiagnosis and overtreatment of thyroid cancer: A population-based temporal trend study
2017 · cited by 163
A population-based study on thyroid cancer demonstrates that rising early-stage incidence with stable mortality strongly reflects significant overdiagnosis and resulting overtreatment.
Practical Strategy to Mitigate Overdiagnosis in Asian Low-dose Computed Tomography Lung Cancer Screening.
2026 · cited by 2
Low-dose CT screening for lung cancer reduces mortality but risks substantial overdiagnosis and overtreatment, particularly among populations with subsolid nodules.
East-West Disparities in Lung Cancer Screening: Subsolid Nodule Prevalence, Interval Growth, and Decision-Making Analysis.
2026 · cited by 0
Overdiagnosis remains a critical concern in lung cancer screening across both Eastern and Western clinical contexts.
Prostate Cancer Screening in Contemporary Era: PSA-Based Testing and Risk-Adapted Approaches.
2026 · cited by 0
Prostate cancer screening utilizing traditional PSA testing has historically been limited by substantial downstream overdiagnosis and overtreatment.